(BW) Janssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis

Press/Media: Press / Media

PeriodApr 23 2015

Media coverage

1

Media coverage

  • Title(BW) Janssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletScottrade
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz